SI2301576T1 - Therapeutic use of Anti-CS1 Antibodies - Google Patents

Therapeutic use of Anti-CS1 Antibodies

Info

Publication number
SI2301576T1
SI2301576T1 SI200431948T SI200431948T SI2301576T1 SI 2301576 T1 SI2301576 T1 SI 2301576T1 SI 200431948 T SI200431948 T SI 200431948T SI 200431948 T SI200431948 T SI 200431948T SI 2301576 T1 SI2301576 T1 SI 2301576T1
Authority
SI
Slovenia
Prior art keywords
antibodies
therapeutic use
therapeutic
Prior art date
Application number
SI200431948T
Other languages
Slovenian (sl)
Inventor
Marna Williams
J. Yun Tso
Nicolas F. Landolfi
Gao Liu
Original Assignee
Abbott Biotherapeutics Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Priority claimed from US10/982,357 external-priority patent/US7709610B2/en
Application filed by Abbott Biotherapeutics Corp. filed Critical Abbott Biotherapeutics Corp.
Publication of SI2301576T1 publication Critical patent/SI2301576T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SI200431948T 2004-03-29 2004-11-08 Therapeutic use of Anti-CS1 Antibodies SI2301576T1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55762104P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
EP10180748A EP2301576B1 (en) 2004-03-29 2004-11-08 Therapeutic use of Anti-CS1 Antibodies

Publications (1)

Publication Number Publication Date
SI2301576T1 true SI2301576T1 (en) 2013-02-28

Family

ID=44597272

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431948T SI2301576T1 (en) 2004-03-29 2004-11-08 Therapeutic use of Anti-CS1 Antibodies

Country Status (9)

Country Link
JP (1) JP4758984B2 (en)
CY (1) CY1115003T1 (en)
DK (1) DK2301576T3 (en)
ES (1) ES2393539T3 (en)
HK (2) HK1099699A1 (en)
HR (1) HRP20120975T1 (en)
IL (1) IL243687A0 (en)
PT (1) PT2301576E (en)
SI (1) SI2301576T1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149021A2 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
SG11202010496WA (en) * 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
CN112442126B (en) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 Monoclonal antibody of anti-human CS1 antigen and CAR-T cell thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123617A1 (en) * 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof

Also Published As

Publication number Publication date
HK1099699A1 (en) 2007-08-24
DK2301576T3 (en) 2012-12-10
JP4758984B2 (en) 2011-08-31
IL243687A0 (en) 2016-04-21
ES2393539T3 (en) 2012-12-26
CY1115003T1 (en) 2016-12-14
PT2301576E (en) 2012-12-20
JP2007530675A (en) 2007-11-01
HK1155670A1 (en) 2012-05-25
HRP20120975T1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
CY2016035I1 (en) THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
IL183458A0 (en) Anti-il-1r1 single domain antibodies and therapeutic uses
IL178593A (en) Fcγriib-specific antibodies and methods of use thereof
IL176958A0 (en) Compounds and methods of use
EP1789027A4 (en) Therapeutic use of anti-tf-antigen antibody
SI1587542T1 (en) Use of anti-cd100 antibodies
GB0419850D0 (en) Therapeutic agents
GB0416396D0 (en) Therapeutic agents
EP1806147A4 (en) Use of immunesuppressant receptor
EP1812451A4 (en) Compounds and methods of use thereof
GB0403780D0 (en) Therapeutic agents
EP1740541A4 (en) Therapeutic formulations of desoxyepothilones
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
GB0419192D0 (en) Therapeutic agents
GB0423103D0 (en) Therapeutic agents
GB0417939D0 (en) Therapeutic agents
GB0400193D0 (en) Therapeutic agents
GB0427701D0 (en) Therapeutic agents
GB0403779D0 (en) Therapeutic agents
GB0416934D0 (en) Therapeutic agents
GB0402918D0 (en) Therapeutic agents
GB0400196D0 (en) Therapeutic agents
GB0421533D0 (en) Therapeutic use
GB0401256D0 (en) Production of human antibodies
GB0425532D0 (en) Therapeutic compounds and methods for their preparation and use